title: Hydromorphone-OROS formulation.
abstract: BACKGROUND
  Hydromorphone is a semi-synthetic opioid approved in the USA for the treatment and relief of moderate to severe pain and postoperative pain. However, the compound is short-acting, and there is no extended-release formulation clinically available. A previous hydromorphone extended-release formulation that successfully came to market was subsequently withdrawn on account of safety concerns. Clinical need supports the presence of an extended-release formulation of hydromorphone.
  
  
  METHODS
  Medline articles showing from a search of 'hydromorphone and OROS' were included in the review. In addition, searches were done relating to published data regarding regulatory affairs dealing with this specific topic. Physicians prescribing information for hydromorphone was also reviewed.
  
  
  RESULTS
  The reader will gain an increased understanding of the use of an extended-release formulation of hydromorphone using the OROS technology and will appreciate that this technology has safety advantages compared with previous extended-release formulations of hydromorphone.
  
  
  CONCLUSIONS
  Hydromorphone-OROS is an effective agent for the long-acting control of pain and a welcome addition to other available opioid formulations.
authors.affiliation: Duke University Medical Center, DUMC 3309, Durham, NC 27710, USA. harold.goforth@duke.edu
authors.forename: Harold W
authors.initials: HW
authors.lastname: Goforth
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D003692:Delayed-Action Preparations; D006801:Humans; D004091:Hydromorphone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D010149:Postoperative Pain / Q000188:drug therapy; D012720:Severity of Illness Index
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D004091:Hydromorphone